FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to compounds presented by general formula (I) and their pharmaceutically acceptable salts. The compounds of the invention possess activity of D2 receptor agonist. In general formula (I) R1 represents a cyano group; each R2 and R3 independently represents a hydrogen atom, C1-6alkyl group, C1-7acyl group or (C1-6alkoxy)-C(O)-; R4 represents a hydrogen atom, C1-6alkyl group or halogen-C1-6alkyl group; the other radicals are presented in the patent claim. The invention also refers to individual compounds and pharmaceutical compositions containing an effective amount of the compound of the invention.
EFFECT: produced are the new compounds possessing the activity of D2 receptor agonist.
14 cl, 14 tbl, 433 ex
Title | Year | Author | Number |
---|---|---|---|
C-4" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | 2012 |
|
RU2599718C2 |
NEW HYDROXAMIC ACID DERIVATIVE | 2011 |
|
RU2575129C2 |
DERIVATIVES OF α-SUBSTITUTED GLYCINEAMIDE | 2014 |
|
RU2670982C2 |
PIRAZOLOQINOLINE DERIVATIVE | 2012 |
|
RU2605096C2 |
NOVEL AMINE DERIVATIVE OR SALT THEREOF | 2013 |
|
RU2668550C2 |
NEW BENZOAZEPINE DERIVATIVE AND ITS MEDICAL APPLICATION | 2013 |
|
RU2642783C2 |
NEW PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (1) | 2005 |
|
RU2330021C2 |
DISPIROPYRROLIDINE DERIVATIVES | 2012 |
|
RU2612534C2 |
TETRAHYDROCARBOLINE DERIVATIVE | 2011 |
|
RU2572818C2 |
C-PHENYL GLYCITOL COMPOUND FOR TREATING DIABETES | 2007 |
|
RU2437876C2 |
Authors
Dates
2016-01-20—Published
2012-03-12—Filed